While a Cepheid GeneExpert test was a top Part B code in 2024 (here), most new technologies for infectious disease, including point-of-care, have had a slow slog. One barrier is that CMS bundles payment for these tests in the ER setting (where CMS only pays for human DNA-RNA tests).
According to a report in 360Dx, T2 Biosystems will wind down operations. They note that trading of stock suspended as far back as February 2025.
360Dx writes, "The firm said it has "extremely limited cash and significant liabilities" and has concluded that "a wind down is the only viable path forward." ...Its core technology for pathogen identification and antimicrobial resistance testing directly from blood samples relied on magnetic resonance imaging and PCR.
Along the way, in summer 2019, its T2 Bacteria Panel won NTAP (inpatient add on payment) for FY2020. The add-on to the DRG (which is often $5000-15000) was $97, which applied only to the hospital's Part B FFS inpatients.
